Skip to content
+49 3371 6199600info@celltrend.deIm Biotechnologiepark 3 TGZ II, 14943 Luckenwalde
  • Contact
  • German
  • English
topbar - English
Search:
Suche
CellTrend Luckenwalde
Auftragsforschung, Antikörperdiagnostik
CellTrend LuckenwaldeCellTrend Luckenwalde
  • Company Profile
    • Newsroom
    • Board of management
    • Quality Management System
    • Referenzen
    • Partners
  • POTS – CFS/ME – SFN – Long Covid
    • Information for patients
  • AT1R-Antibody ELISA
    • Product information
    • Transplantation
    • Systemic sclerosis
    • Literature
  • ELISA
    • GPCR-Antibodies
    • In vitro Diagnostics (human)
    • Research use only
    • Food analysis
    • Contract research
    • Contract manufacturing
  • Consulting
  • Fluorescent Cells
  • Cell culture test systems
    • Oncology
    • Inflammatory test systems
    • Contract research
  • Company Profile
    • Newsroom
    • Board of management
    • Quality Management System
    • Referenzen
    • Partners
  • POTS – CFS/ME – SFN – Long Covid
    • Information for patients
  • AT1R-Antibody ELISA
    • Product information
    • Transplantation
    • Systemic sclerosis
    • Literature
  • ELISA
    • GPCR-Antibodies
    • In vitro Diagnostics (human)
    • Research use only
    • Food analysis
    • Contract research
    • Contract manufacturing
  • Consulting
  • Fluorescent Cells
  • Cell culture test systems
    • Oncology
    • Inflammatory test systems
    • Contract research

Alzheimer’s Disease research

You are here:
  1. Home
  2. News
  3. Alzheimer’s Disease research

Dr. Lasse Giil et al., Haraldsplass Hospital Bergen, describes the association between multiple antibodies an neuropsychiatric symptoms and Mortality in Alzheimer’s patients.

https://www.ncbi.nlm.nih.gov/pubmed/29914018

22. June 2018

News
  • Gutenberg COVID-19 study shows significant change in ACE-II titers after corona vaccination 28. July 2022
  • CellTrend sponsors graduation gift for students 8. July 2022
  • Long-COVID network founded in Brandenburg 24. June 2022
  • New antibodies for Long-Covid patients 12. May 2022
  • study identifies new autoantibodies as potential biomarkers for COVID-19 severity 21. March 2022
  • CellTrend donates for refugees from Ukraine 11. March 2022
+49 3371 6199600 info@celltrend.de Im Biotechnologiepark 3 TGZ II, 14943 Luckenwalde
  • Data protection declaration
  • Imprint
bottombar - English

FacebookInstagram

Go to Top